1. A pharmacology student is reviewing the historical origins of the monoamine hypothesis of depression. Which observation from the 1950s most directly provided the initial pharmacological evidence that monoamine depletion could cause depressive symptoms?
A) Imipramine was found to block the reuptake of norepinephrine and serotonin from the synaptic cleft, producing mood elevation in hospitalized patients.
B) Reserpine, used clinically to treat hypertension, caused depression in a substantial proportion of patients through depletion of monoamines from presynaptic storage vesicles.
C) Iproniazid, developed as an antitubercular drug, was found to elevate mood and was subsequently identified as an inhibitor of monoamine reuptake transporters.
D) Tryptophan depletion studies in healthy volunteers reliably produced full depressive episodes, confirming that reduced serotonin availability is sufficient to cause depression.
E) Electroconvulsive therapy was shown to increase synaptic monoamine concentrations, providing a mechanistic link between monoamine elevation and mood improvement.
ANSWER: B
Rationale:
Option B is correct. Reserpine depletes monoamines — specifically norepinephrine, dopamine, and serotonin — from presynaptic storage vesicles by irreversibly blocking the vesicular monoamine transporter (VMAT). Its capacity to cause clinical depression in a significant proportion of treated hypertensive patients provided the first direct pharmacological evidence that reduction of monoaminergic neurotransmission could produce depressive symptoms, and this observation became one of the two founding pillars of the monoamine hypothesis.
Option A: Option A is incorrect. Imipramine does block norepinephrine and serotonin reuptake transporters and does produce mood elevation, but imipramine came after the reserpine observation and contributed to the hypothesis as evidence for the therapeutic direction (enhancing monoamines improves mood) rather than as the depletion-causes-depression evidence that reserpine provided.
Option C: Option C is incorrect. Iproniazid is correctly identified as a drug that elevates mood and is associated with the monoamine hypothesis, but it was identified as a monoamine oxidase inhibitor (MAOI) — blocking enzymatic degradation of monoamines — not as an inhibitor of reuptake transporters. The mechanism described in this option is wrong.
Option D: Option D is incorrect. Tryptophan depletion studies do not reliably produce depression in healthy volunteers without a personal or family history of mood disorder — this finding is explicitly one of the limitations of the monoamine hypothesis, not supporting evidence for it. The statement in this option is factually inverted.
Option E: Option E is incorrect. While electroconvulsive therapy is an effective antidepressant treatment and does affect monoaminergic systems, it was not part of the 1950s observations that gave rise to the monoamine hypothesis, and the mechanistic claim stated here is an oversimplification not used as a founding evidence base for the hypothesis.
2. A first-year medical student asks about the primary molecular mechanism responsible for the therapeutic effects of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and sertraline. Which of the following correctly identifies the primary pharmacological target of this drug class?
A) Inhibition of monoamine oxidase (MAO), reducing enzymatic degradation of serotonin, norepinephrine, and dopamine in the presynaptic terminal.
B) Blockade of presynaptic alpha-2 adrenergic autoreceptors, disinhibiting the release of both norepinephrine and serotonin from presynaptic terminals.
C) Simultaneous inhibition of both the serotonin transporter (SERT) and the norepinephrine transporter (NET), producing dual monoaminergic enhancement.
D) Selective inhibition of the serotonin transporter (SERT), reducing reuptake of serotonin from the synaptic cleft and increasing serotonergic neurotransmission.
E) Blockade of postsynaptic serotonin 5-HT2A receptors combined with inhibition of SERT, reducing serotonin-mediated adverse effects while maintaining antidepressant efficacy.
ANSWER: D
Rationale:
Option D is correct. SSRIs selectively inhibit SERT, the presynaptic transporter responsible for removing serotonin from the synaptic cleft. This blockade reduces serotonin reuptake, increases synaptic serotonin concentrations, and enhances serotonergic neurotransmission. The selectivity for SERT over other monoamine transporters and receptors distinguishes the SSRIs from older agents and underlies their relatively favorable tolerability profile compared to tricyclic antidepressants.
Option A: Option A is incorrect. MAO inhibition is the mechanism of monoamine oxidase inhibitors (MAOIs) such as phenelzine and tranylcypromine, not SSRIs. These are a distinct drug class with different mechanisms, drug interaction profiles, and dietary restrictions.
Option B: Option B is incorrect. Blockade of presynaptic alpha-2 adrenergic autoreceptors is the primary mechanism of mirtazapine, which belongs to the noradrenergic and specific serotonergic antidepressant (NaSSA) class. Mirtazapine disinhibits NE and 5-HT release through this mechanism, which is pharmacologically distinct from reuptake inhibition.
Option C: Option C is incorrect. Simultaneous SERT and NET inhibition describes the serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine, duloxetine, and levomilnacipran. SSRIs produce clinically meaningful inhibition primarily at SERT and lack the significant NET inhibition that characterizes the SNRI class.
Option E: Option E is incorrect. Combined SERT inhibition with postsynaptic 5-HT2A blockade describes the mechanism of serotonin antagonist and reuptake inhibitors (SARIs) such as trazodone and nefazodone, not SSRIs. The SSRI class does not include significant 5-HT2A receptor antagonism as part of its primary pharmacological profile.
3. A resident initiates sertraline in a patient with moderate major depressive disorder and calls the attending two weeks later reporting that the patient has seen no improvement and is asking for a higher dose. Which of the following statements most accurately characterizes the expected time course of antidepressant response and the role of early dose escalation?
A) Clinically meaningful antidepressant response typically requires two to four weeks of continuous treatment, and dose escalation within the first two weeks is unlikely to accelerate onset and may increase adverse effects without therapeutic benefit.
B) The absence of response at two weeks indicates treatment failure, and switching to a different antidepressant class at this point is the recommended next step according to standard guidelines.
C) SSRI blockade of the serotonin transporter produces a measurable elevation in synaptic serotonin within the first 24 to 48 hours, and this early biochemical response should translate into early clinical improvement within the first week.
D) Doubling the dose of sertraline at two weeks is appropriate because higher doses produce proportionally faster autoreceptor desensitization, compressing the lag period to one week or less.
E) The two-to-four-week lag period applies only to tricyclic antidepressants and monoamine oxidase inhibitors; SSRIs typically produce clinical improvement within five to seven days due to their greater selectivity for SERT.
ANSWER: A
Rationale:
Option A is correct. The two-to-four-week lag before clinically meaningful antidepressant response is a consistent finding across all antidepressant classes — SSRIs, SNRIs, TCAs, and MAOIs alike — and is not resolved by dose escalation beyond the therapeutic range. The mechanistic basis involves receptor adaptations and neuroplasticity changes that require sustained exposure, not simply higher drug concentrations. Patients should be counseled explicitly about this timeline before initiation, and an adequate trial is defined as four to six weeks at a therapeutic dose.
Option B: Option B is incorrect. Four to six weeks at an adequate dose constitutes the minimum for an adequate antidepressant trial. Switching at two weeks risks discarding a potentially effective treatment before it has had sufficient time to produce its downstream cellular and receptor adaptations.
Option C: Option C is incorrect. While SERT blockade does occur rapidly — within hours of the first dose — the early biochemical change at the transporter does not translate into early clinical improvement. The autoreceptor negative feedback, neuroplasticity adaptations, and downstream receptor changes that are necessary for therapeutic response require the full two-to-four-week interval.
Option D: Option D is incorrect. Dose escalation does not compress the lag period because the delay is not a simple function of drug concentration. The rate-limiting steps — autoreceptor desensitization, BDNF upregulation, hippocampal neuroplasticity — are time-dependent biological processes that do not respond proportionally to higher plasma drug levels.
Option E: Option E is incorrect. The two-to-four-week lag applies equally to SSRIs as to all other antidepressant classes. SERT selectivity does not accelerate clinical response; it improves tolerability. There is no evidence that SSRIs produce antidepressant effects within five to seven days as a class property.
4. When an SSRI is first administered, synaptic serotonin rises in the vicinity of the serotonergic cell body in the dorsal raphe nucleus. This acutely activates receptors that suppress neuronal firing and partially counteract the intended effect. Which receptor subtype is responsible for this negative feedback, and what happens to it over two to four weeks of continued SSRI treatment?
A) Postsynaptic 5-HT2A receptors in the prefrontal cortex become upregulated over two to four weeks, increasing their sensitivity to serotonin and amplifying the downstream antidepressant signal.
B) Presynaptic dopamine D2 autoreceptors on serotonergic neurons in the raphe nucleus desensitize over two to four weeks, removing inhibition of serotonin synthesis and increasing serotonergic output.
C) Somatodendritic 5-HT1A autoreceptors on serotonergic cell bodies in the dorsal raphe nucleus desensitize and downregulate over two to four weeks, removing the inhibitory brake and allowing serotonergic output to increase substantially.
D) Presynaptic norepinephrine alpha-2 autoreceptors on serotonergic terminals desensitize over two to four weeks, disinhibiting serotonin release independently of SERT blockade.
E) Postsynaptic NMDA glutamate receptors in hippocampal circuits become sensitized over two to four weeks of SSRI exposure, and this glutamatergic adaptation is the primary event linking transporter blockade to clinical response.
ANSWER: C
Rationale:
Option C is correct. The 5-HT1A somatodendritic autoreceptors located on serotonergic cell bodies in the dorsal raphe nucleus act as a negative feedback brake: when acute SERT blockade raises local serotonin near the cell body, these autoreceptors are activated, suppressing serotonergic neuron firing and limiting 5-HT output to terminal fields. With sustained SSRI exposure over two to four weeks, these autoreceptors desensitize and downregulate, removing the inhibitory brake and allowing serotonergic output into prefrontal and limbic projections to increase substantially. This desensitization timeline maps directly onto the clinical onset of antidepressant response.
Option A: Option A is incorrect. Postsynaptic 5-HT2A receptors undergo downregulation — not upregulation — with chronic antidepressant treatment. This downregulation is a convergent adaptation produced by structurally diverse antidepressants and has been proposed as a correlate of therapeutic response, but the receptor involved in the acute negative feedback on neuronal firing is the presynaptic somatodendritic 5-HT1A autoreceptor, not the postsynaptic 5-HT2A receptor.
Option B: Option B is incorrect. Dopamine D2 autoreceptors are relevant to dopaminergic neurons, not serotonergic neurons in the raphe nucleus. The inhibitory autoreceptor on the serotonergic cell body that limits firing in response to acute SSRI-induced serotonin elevation is the 5-HT1A receptor, not a dopamine receptor.
Option D: Option D is incorrect. Alpha-2 adrenergic autoreceptors on noradrenergic terminals and heteroreceptors on serotonergic terminals are the target of mirtazapine's mechanism of action, but they are not the primary autoreceptors responsible for the negative feedback that limits serotonergic output during early SSRI treatment. The 5-HT1A somatodendritic receptor is the established mechanistic explanation for the SSRI lag.
Option E: Option E is incorrect. NMDA glutamate receptor sensitization in hippocampal circuits is not the established mechanistic explanation for the lag period in SSRI response. NMDA receptor blockade is relevant to ketamine's rapid antidepressant mechanism, which bypasses the lag period precisely because it does not depend on the slow autoreceptor desensitization timeline that governs SSRI onset.
5. A 34-year-old woman with major depressive disorder and a history of bulimia nervosa is referred for antidepressant initiation. Her psychiatrist considers bupropion but ultimately selects a different agent. Which of the following best describes both bupropion's mechanism of action and the pharmacological basis for avoiding it in this patient?
A) Bupropion inhibits SERT and NET, producing dual serotonergic and noradrenergic enhancement; it is avoided in bulimia nervosa because serotonergic excess can precipitate purging behavior in susceptible patients.
B) Bupropion inhibits MAO irreversibly, increasing monoamine availability; it is avoided in eating disorders because MAO inhibition in malnourished patients markedly increases the risk of hypertensive crisis from dietary tyramine.
C) Bupropion inhibits NET and the serotonin transporter (SERT) with equal potency; it is avoided in bulimia nervosa because high-dose serotonin reuptake inhibition lowers seizure threshold in patients with electrolyte abnormalities.
D) Bupropion blocks postsynaptic dopamine D2 receptors and inhibits NET; it is avoided in bulimia nervosa because D2 blockade reduces satiety signaling and worsens binge-purge cycles.
E) Bupropion inhibits the norepinephrine transporter (NET) and the dopamine transporter (DAT) with minimal activity at SERT; it carries a dose-dependent seizure risk that makes it contraindicated in patients with seizure disorders and in eating disorders involving purging behavior.
ANSWER: E
Rationale:
Option E is correct. Bupropion is the sole clinically available norepinephrine-dopamine reuptake inhibitor (NDRI), inhibiting NET and DAT while having minimal effect on SERT. This lack of serotonergic activity distinguishes it pharmacologically from SSRIs and SNRIs and accounts for its markedly more favorable sexual side effect profile. Its dose-dependent seizure risk is the basis for its contraindication in patients with seizure disorders and in eating disorders involving purging behavior such as bulimia nervosa and anorexia nervosa with purging — patients who purge are at elevated seizure risk through electrolyte disturbances, and bupropion compounds this risk.
Option A: Option A is incorrect. Bupropion does not inhibit SERT to any clinically significant degree; its mechanism is NET and DAT inhibition. The explanation for its avoidance in bulimia nervosa involves seizure risk from the dose-dependent pharmacological property of the drug combined with purging-related electrolyte disturbances, not serotonergic excess precipitating purging.
Option B: Option B is incorrect. Bupropion is not an MAO inhibitor of any kind. Irreversible MAO inhibition and the associated tyramine interaction are properties of the MAOI class (phenelzine, tranylcypromine), not bupropion.
Option C: Option C is incorrect. Bupropion does not inhibit SERT with equal potency to NET; its serotonergic activity is minimal. The framing of equal SERT and NET inhibition describes the SNRI class, not bupropion. The seizure mechanism stated in this option is also pharmacologically inaccurate — the seizure risk from bupropion is an intrinsic dose-dependent property of the drug, not mediated through serotonin reuptake inhibition or electrolyte effects specifically.
Option D: Option D is incorrect. Bupropion does not block postsynaptic dopamine D2 receptors; it inhibits the dopamine reuptake transporter (DAT), increasing synaptic dopamine availability rather than blocking its postsynaptic effects. D2 blockade is the mechanism of antipsychotic drugs, not antidepressants.
6. A pharmacology instructor asks students to explain why mirtazapine increases synaptic norepinephrine and serotonin concentrations without blocking monoamine reuptake transporters. Which of the following correctly describes the mechanism by which mirtazapine achieves this effect?
A) Mirtazapine inhibits monoamine oxidase type A (MAO-A) selectively, reducing degradation of norepinephrine and serotonin in the synaptic cleft while sparing dopamine metabolism.
B) Mirtazapine blocks presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, removing the inhibitory feedback that normally limits norepinephrine and serotonin release from presynaptic terminals.
C) Mirtazapine inhibits both SERT and NET with high affinity while simultaneously blocking postsynaptic 5-HT2 receptors, redirecting serotonergic signaling toward 5-HT1A-mediated pathways.
D) Mirtazapine activates postsynaptic 5-HT1A receptors directly as a full agonist, bypassing the need for increased synaptic serotonin concentrations to produce antidepressant effects.
E) Mirtazapine blocks the vesicular monoamine transporter (VMAT), transiently increasing cytoplasmic monoamine availability before degradation by MAO, which produces a net increase in synaptic release.
ANSWER: B
Rationale:
Option B is correct. Mirtazapine's primary mechanism for increasing norepinephrine and serotonin release is blockade of presynaptic alpha-2 adrenergic autoreceptors — located on noradrenergic terminals and serving as negative feedback sensors for synaptic norepinephrine — and alpha-2 heteroreceptors on serotonergic terminals that normally limit 5-HT release. By blocking these inhibitory receptors, mirtazapine removes the feedback brake on both noradrenergic and serotonergic neurons, disinhibiting release without directly touching reuptake transporters. Mirtazapine also blocks postsynaptic 5-HT2A, 5-HT2C, and 5-HT3 receptors, and has potent H1 antihistaminic activity that produces its characteristic sedation.
Option A: Option A is incorrect. Mirtazapine does not inhibit MAO. MAO inhibition is the mechanism of the MAOI drug class (phenelzine, tranylcypromine, selegiline), not mirtazapine. Confusing these mechanisms is a common error; the key distinction is that mirtazapine increases release by removing autoreceptor inhibition, while MAOIs increase availability by preventing enzymatic degradation.
Option C: Option C is incorrect. Mirtazapine does not have clinically significant inhibitory activity at SERT or NET. It is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA) precisely because its enhancement of monoaminergic neurotransmission is achieved through receptor blockade rather than reuptake inhibition.
Option D: Option D is incorrect. Mirtazapine is not a 5-HT1A receptor agonist. Partial 5-HT1A agonism is the mechanism of vilazodone (combined with SERT inhibition) and buspirone (used as an anxiolytic and antidepressant augmenting agent). Mirtazapine's postsynaptic serotonergic effects involve blocking 5-HT2 and 5-HT3 receptors, not activating 5-HT1A.
Option E: Option E is incorrect. Blockade of the vesicular monoamine transporter (VMAT) is the mechanism of reserpine, which depletes monoamine stores and can cause depression — the pharmacological opposite of what an antidepressant should do. Mirtazapine has no VMAT-blocking activity.
7. A patient prescribed paroxetine at a standard dose of 20 mg daily experiences significantly more adverse effects than expected, including pronounced sedation, dry mouth, and urinary hesitancy, despite the dose being within the normal therapeutic range. Pharmacogenomic testing reveals she is a CYP2D6 poor metabolizer. Which of the following best explains the clinical significance of this finding for antidepressant prescribing?
A) CYP2D6 poor metabolizers lack functional CYP2D6 enzyme activity, leading to substantially higher plasma concentrations of CYP2D6-metabolized antidepressants such as paroxetine, fluoxetine, and tricyclic antidepressants at standard doses.
B) CYP2D6 poor metabolizers have reduced CYP3A4 activity as a compensatory consequence of CYP2D6 deficiency, resulting in impaired metabolism of a broad range of coadministered drugs across multiple drug classes.
C) CYP2D6 poor metabolizer status means the patient produces excess of the active metabolite relative to the parent drug, because the alternative metabolic pathway produces a more pharmacologically potent compound.
D) CYP2D6 poor metabolizers are unable to convert prodrugs to their active forms; since paroxetine requires CYP2D6 activation, poor metabolizers achieve subtherapeutic concentrations of the active drug at standard doses.
E) CYP2D6 poor metabolizer status affects only the rate of drug absorption from the gastrointestinal tract and does not influence steady-state plasma drug concentrations during chronic dosing.
ANSWER: A
Rationale:
Option A is correct. CYP2D6 is a major metabolic pathway for paroxetine, fluoxetine, venlafaxine, and tricyclic antidepressants among others. Approximately 7% to 10% of individuals of European ancestry are poor metabolizers who lack functional CYP2D6 activity due to loss-of-function genetic variants. In the absence of this metabolic pathway, these drugs accumulate to substantially higher plasma concentrations at standard doses — potentially doubling or tripling expected levels — resulting in enhanced pharmacodynamic effects and a greater burden of adverse effects, exactly as observed in this patient. Dose reduction or selection of an antidepressant not dependent on CYP2D6 is the appropriate management response.
Option B: Option B is incorrect. CYP2D6 poor metabolizer status does not reduce CYP3A4 activity. Each CYP isoform is encoded by a separate gene and is independently regulated; deficiency in one isoform has no compensatory consequence on the activity of another. CYP3A4 activity is unaffected by CYP2D6 genotype.
Option C: Option C is incorrect. Paroxetine is not a prodrug requiring CYP2D6 activation; it is an active compound directly inhibiting SERT. The description of poor metabolizers producing excess active metabolite inverts the pharmacological reality — in the absence of CYP2D6, the parent drug accumulates rather than being converted to a metabolite, because CYP2D6 is a clearance pathway for paroxetine, not an activation pathway.
Option D: Option D is incorrect. Paroxetine is not a prodrug. Prodrug activation by CYP2D6 is relevant to codeine (converted to morphine) and tramadol, not to antidepressants in the SSRI class. Poor metabolizers of paroxetine accumulate the active drug itself at higher-than-expected concentrations, not subtherapeutic ones.
Option E: Option E is incorrect. CYP2D6 governs hepatic first-pass and systemic metabolic clearance, both of which directly determine steady-state plasma concentrations. The claim that CYP2D6 affects only absorption rate and not steady-state concentrations is pharmacokinetically incorrect — clearance, not absorption rate, is the primary determinant of steady-state drug levels.
8. A psychiatrist plans to switch a patient from fluoxetine to phenelzine, an irreversible MAOI, after the patient fails to respond to two SSRI trials. The psychiatrist is aware that a washout period is required before initiating phenelzine. Which of the following correctly explains why the required washout period for fluoxetine is substantially longer than for other SSRIs, and what the minimum washout duration is?
A) Fluoxetine is highly protein-bound and must be fully displaced from albumin binding sites before MAOI initiation; the washout period of two weeks reflects the time required for protein binding equilibration rather than drug elimination.
B) Fluoxetine undergoes extensive enterohepatic recirculation, creating a tissue reservoir that releases drug back into the circulation over several weeks; the standard washout is three weeks to account for this recycling.
C) Fluoxetine inhibits CYP2D6, and this enzyme inhibition persists for two weeks after the drug is discontinued, requiring a washout to prevent phenelzine accumulation through impaired CYP2D6-mediated metabolism.
D) Fluoxetine is metabolized to norfluoxetine, an active metabolite with a half-life of seven to fifteen days that inhibits SERT with similar potency to the parent compound; the combined effective duration requires a five-week washout before initiating an irreversible MAOI.
E) Fluoxetine's high lipophilicity leads to accumulation in adipose tissue, from which it is slowly released over several weeks; the five-week washout reflects the time required for complete redistribution out of fat stores.
ANSWER: D
Rationale:
Option D is correct. Fluoxetine is metabolized by CYP2D6 to norfluoxetine, an active metabolite that has a half-life of seven to fifteen days and inhibits SERT with potency comparable to the parent drug. This extraordinarily long active metabolite half-life means that even after fluoxetine itself is cleared, meaningful SERT inhibition persists for weeks. The combination of fluoxetine plus norfluoxetine effective activity requires a five-week washout period before initiating an irreversible MAOI such as phenelzine, because concurrent SERT inhibition and MAO inhibition carries a serious risk of serotonin syndrome — potentially life-threatening accumulation of synaptic serotonin. No other commonly prescribed SSRI has an active metabolite with this duration of action.
Option A: Option A is incorrect. While fluoxetine is highly protein-bound, protein binding equilibration is not the pharmacokinetic basis for the washout requirement. The clinical concern is the risk of serotonin syndrome from combined SERT and MAO inhibition, which persists as long as norfluoxetine is present in functionally significant concentrations. Protein displacement is not the rate-limiting factor.
Option B: Option B is incorrect. Fluoxetine does not undergo clinically significant enterohepatic recirculation. The prolonged washout requirement is entirely explained by the long half-life of its active metabolite norfluoxetine, not by a recirculation reservoir.
Option C: Option C is incorrect. While fluoxetine does inhibit CYP2D6, and this inhibition does persist briefly after discontinuation, the primary and clinically authoritative reason for the five-week washout before MAOI initiation is the prolonged serotonergic activity of norfluoxetine — not CYP2D6 enzyme inhibition affecting phenelzine metabolism.
Option E: Option E is incorrect. While fluoxetine is lipophilic, adipose tissue accumulation and redistribution are not the pharmacokinetic explanation for the extended washout period. The mechanism is norfluoxetine's long half-life maintaining SERT inhibition, which is the specific drug interaction hazard relevant to MAOI coadministration.
9. A 28-year-old man is brought to the emergency department following an intentional overdose of amitriptyline. A consulting nephrologist asks whether emergent hemodialysis would be useful to accelerate drug removal. Which pharmacokinetic property of antidepressants as a class explains why dialysis is largely ineffective for removing these drugs?
A) Antidepressants are predominantly eliminated by active renal tubular secretion, and dialysis bypasses this pathway entirely, leaving the dominant clearance mechanism intact and making dialysis redundant rather than ineffective.
B) Antidepressants are extensively metabolized to pharmacologically inactive compounds within the first 30 minutes of absorption, meaning that by the time dialysis could be initiated, the parent drug has already been cleared.
C) Antidepressants have large apparent volumes of distribution, typically 10 to 50 L/kg, reflecting extensive tissue binding; because plasma drug concentrations represent only a small fraction of total body drug burden, dialysis removes only a negligible amount of the total drug present.
D) Antidepressants are almost entirely ionized at physiological plasma pH, preventing them from crossing the dialysis membrane; increasing the pH of the dialysate is required before any meaningful drug removal can occur.
E) Antidepressants form irreversible covalent bonds with plasma proteins, and dialysis membranes cannot separate covalently bound drug-protein complexes, rendering the technique mechanically incapable of drug removal.
ANSWER: C
Rationale:
Option C is correct. Antidepressants as a class are highly lipophilic and have large apparent volumes of distribution — generally in the range of 10 to 50 L/kg — reflecting extensive partitioning into peripheral tissues including brain, adipose, and muscle relative to the plasma compartment. Because plasma contains only a small fraction of the total drug present in the body at any given time, hemodialysis, which clears drug from the plasma compartment, removes a pharmacologically negligible amount of the total drug burden. Dialysis cannot access the drug sequestered in tissues. This pharmacokinetic principle — not any specific chemical property of the dialysis membrane — is why dialysis is ineffective for antidepressant overdose management.
Option A: Option A is incorrect. Antidepressants are predominantly eliminated by hepatic metabolism through the CYP enzyme system, not by renal tubular secretion. Renal clearance plays a minor role for most antidepressants. The ineffectiveness of dialysis in overdose is not due to dialysis bypassing a renally dominant clearance pathway; it is due to the large Vd preventing meaningful drug access from the plasma compartment.
Option B: Option B is incorrect. Antidepressants are not extensively metabolized within 30 minutes of absorption; they undergo hepatic first-pass metabolism over a standard absorption and distribution time course, with Tmax typically one to six hours after oral dosing. Plasma concentrations in overdose can remain elevated and clinically significant for many hours.
Option D: Option D is incorrect. While the ionization state of a drug does influence dialysis efficiency, antidepressants are not predominantly ionized at physiological pH in a manner that mechanically prevents membrane passage. The primary pharmacokinetic reason for dialysis inefficacy is the large Vd and tissue sequestration, not ionization at the dialysis membrane.
Option E: Option E is incorrect. Antidepressants do bind extensively to plasma proteins, predominantly albumin and alpha-1-acid glycoprotein, but this binding is reversible — not covalent. Reversible protein binding does reduce the free drug fraction available for dialysis, but the predominant explanation for dialysis inefficacy is the large Vd and tissue distribution, not covalent protein binding.
10. A primary care physician uses the Patient Health Questionnaire-9 (PHQ-9) to monitor a patient's antidepressant treatment. At baseline the patient scored 18, indicating moderately severe depression. At the six-week follow-up visit the patient scores 8. Which of the following correctly applies the standard PHQ-9 definitions of response and remission to this result?
A) The patient has achieved remission, because a score of 8 falls below the moderate depression threshold of 10, and any score below the moderate range represents full symptomatic recovery by PHQ-9 criteria.
B) The patient has achieved neither response nor remission; response requires a reduction to a score of 5 or below, and remission is defined as complete absence of symptoms for at least two consecutive assessment periods.
C) The patient has achieved response and remission; a score of 8 represents a 56% reduction from baseline meeting the response criterion, and any score below 10 qualifies as remission on the PHQ-9 scale.
D) The patient has achieved remission but not response; remission is defined as a score below 10 on the PHQ-9, while response requires a complete return to a score of zero, indicating full absence of any depressive symptoms.
E) The patient has achieved response but not remission; response requires a 50% or greater reduction in score from baseline, and remission is defined as a score below 5. A reduction from 18 to 8 is a 56% reduction, meeting the response threshold, but a score of 8 does not meet the remission threshold.
ANSWER: E
Rationale:
Option E is correct. By standard PHQ-9 definitions used in clinical practice and research, response is defined as a 50% or greater reduction in total score from baseline, and remission is defined as a score below 5. This patient's score dropped from 18 to 8, a reduction of 10 points — representing a 56% reduction, which meets the response threshold. However, a score of 8 does not fall below 5, so remission has not been achieved. The treatment goal is remission, not merely response, because patients who respond but do not achieve full remission have substantially higher rates of relapse and continued functional impairment than those who achieve a score in the minimal range. This result warrants continued treatment and consideration of further optimization at the next reassessment.
Option A: Option A is incorrect. The PHQ-9 remission threshold is a score below 5, not a score below 10. A score of 8 falls in the mild depression range (5 to 9) and does not constitute remission. Crossing from the moderate to the mild range represents meaningful improvement but not remission by the standard clinical definition.
Option B: Option B is incorrect. Response does not require a reduction to a score of 5 or below — that is the remission threshold. Response requires a 50% or greater reduction from baseline, regardless of the absolute score reached. This patient's 56% reduction meets the response definition. The definition of remission as requiring two consecutive assessment periods is not the standard PHQ-9 criterion.
Option C: Option C is incorrect. Response and remission are distinct outcomes and this option conflates them. A score of 8 does represent a 56% reduction from baseline, which meets the response threshold, but a PHQ-9 score of 8 does not qualify as remission. The remission threshold on the PHQ-9 is a score below 5, not below 10. A score in the mild range (5 to 9) indicates residual symptoms that carry meaningfully elevated relapse risk compared to full remission.
Option D: Option D is incorrect. The threshold of 10 is the lower boundary of moderate depression on the PHQ-9 scale, not the remission threshold. Remission requires a score below 5. Additionally, response does not require a return to a score of zero; a 50% or greater reduction from baseline qualifies as response regardless of the absolute score attained.
11. Researchers investigating the mechanisms of antidepressant action have proposed that brain-derived neurotrophic factor (BDNF) and its high-affinity receptor play a central role in both the pathophysiology of depression and the therapeutic effects of antidepressants. Which of the following statements about this neuroplasticity-based framework is most accurate?
A) BDNF acts through the tropomyosin receptor kinase A (TrkA) receptor; its upregulation in the hippocampus following antidepressant treatment reflects reversal of stress-induced cholinergic neurotoxicity, which is the primary driver of hippocampal volume loss in depression.
B) BDNF acts through the tropomyosin receptor kinase B (TrkB) receptor; chronic antidepressant treatment increases BDNF expression and TrkB signaling in the hippocampus and prefrontal cortex over a timeline that matches the clinical lag period, and ketamine produces rapid antidepressant effects by directly activating TrkB signaling independent of monoamine reuptake inhibition.
C) BDNF acts through the tropomyosin receptor kinase B (TrkB) receptor, but its role is primarily inhibitory; elevated BDNF in the hippocampus during depressive episodes suppresses neurogenesis, and antidepressant treatment works by reducing BDNF to allow precursor cell proliferation to resume.
D) BDNF upregulation is an epiphenomenon of antidepressant treatment with no causal role in clinical response; the therapeutic relevance of the BDNF/TrkB system was disproven when antidepressants were shown to produce clinical benefit in patients with BDNF Val66Met polymorphisms that markedly reduce activity-dependent BDNF secretion.
E) BDNF acts through TrkB receptors predominantly in the amygdala rather than the hippocampus; its role in depression involves potentiation of fear memory consolidation, and antidepressants reduce BDNF activity in the amygdala to attenuate pathological fear responses.
ANSWER: B
Rationale:
Option B is correct. BDNF is a neurotrophin that promotes neuronal survival, dendritic growth, synaptic strengthening, and adult neurogenesis primarily through its high-affinity receptor TrkB. Chronic stress and untreated depression are associated with reduced BDNF expression in the hippocampus and prefrontal cortex. Antidepressant treatment with SSRIs, SNRIs, and TCAs increases BDNF expression and TrkB signaling in these regions, but the time course of this upregulation matches the clinical lag period of two to four weeks rather than the rapid transporter blockade that occurs within hours. This correspondence supports the view that BDNF/TrkB pathway activation — not immediate monoamine elevation — is more closely coupled to therapeutic response. Ketamine and esketamine produce antidepressant effects within hours in treatment-resistant patients by rapidly activating TrkB signaling independently of monoamine reuptake inhibition, providing powerful mechanistic support for the centrality of this pathway.
Option A: Option A is incorrect. BDNF's high-affinity receptor is TrkB, not TrkA. TrkA is the high-affinity receptor for nerve growth factor (NGF), a different neurotrophin. Cholinergic neurotoxicity is not the established mechanism linking stress to hippocampal volume loss in depression; glucocorticoid receptor-mediated mechanisms and reduced neuroplasticity are the relevant pathophysiology.
Option C: Option C is incorrect. BDNF is not inhibitory to hippocampal neurogenesis and its role is not described as elevated during depressive episodes. Depression and chronic stress are associated with reduced BDNF in the hippocampus and prefrontal cortex, and antidepressants increase rather than decrease BDNF expression. The direction of the relationship stated in this option is inverted.
Option D: Option D is incorrect. The BDNF/TrkB system is considered to have a genuine causal role in antidepressant response rather than being an epiphenomenon, based on convergent evidence from animal models, clinical neuroimaging, and the direct TrkB-activating mechanism of ketamine. The Val66Met polymorphism finding does not disprove the pathway's relevance; patients with this variant do show altered antidepressant response characteristics in some studies.
Option E: Option E is incorrect. While BDNF does have roles in the amygdala and fear learning, the neuroplasticity hypothesis of depression and antidepressant action is primarily anchored in hippocampal and prefrontal cortex findings — the brain regions most consistently showing volume reduction in depression and BDNF-mediated restoration with treatment. Describing amygdalar fear-memory attenuation as the primary mechanism inverts the dominant neurobiological framework.
12. A 45-year-old man with treatment-resistant depression and chronic neuropathic pain is prescribed amitriptyline. During a risk counseling session, the prescribing physician explains the overdose risk associated with tricyclic antidepressants (TCAs). Which mechanism is responsible for the life-threatening cardiac toxicity seen in TCA overdose, and which pharmacological property underlies this risk?
A) TCAs block cardiac voltage-gated sodium channels, slowing phase 0 depolarization of the cardiac action potential, which widens the QRS complex, predisposes to ventricular arrhythmias, and can cause refractory cardiovascular collapse in overdose.
B) TCAs inhibit cardiac potassium channels, prolonging ventricular repolarization and extending the QT interval, which predisposes to torsades de pointes and is the primary mechanism of lethal arrhythmia in TCA overdose.
C) TCAs cause fatal cardiac toxicity in overdose primarily through irreversible inhibition of the cardiac sodium-potassium ATPase pump, analogous to digitalis toxicity, leading to intracellular sodium accumulation and cellular depolarization.
D) TCAs produce cardiotoxicity in overdose through their potent alpha-1 adrenergic receptor blockade, causing peripheral vasodilation so severe that cardiac output cannot be maintained, leading to distributive shock without primary arrhythmia.
E) TCAs block cardiac calcium channels of the L-type variety, reducing calcium influx during phase 2 of the action potential, producing negative inotropy and bradycardia that progresses to electromechanical dissociation in severe overdose.
ANSWER: A
Rationale:
Option A is correct. TCAs block cardiac fast voltage-gated sodium channels (Nav1.5), the channels responsible for the rapid phase 0 depolarization of the ventricular action potential. Sodium channel blockade slows conduction velocity through the His-Purkinje system and ventricular myocardium, manifesting as QRS widening on the electrocardiogram. This conduction slowing predisposes to ventricular arrhythmias including ventricular tachycardia and fibrillation and can produce refractory cardiovascular collapse. QRS duration on electrocardiography is used clinically as a real-time marker of TCA toxicity severity: a QRS wider than 100 milliseconds suggests significant sodium channel blockade, and wider than 160 milliseconds is associated with high risk of ventricular arrhythmias. Sodium bicarbonate is used therapeutically to alkalinize the plasma and increase sodium concentration, partially reversing sodium channel blockade.
Option B: Option B is incorrect. While QT prolongation and torsades de pointes are clinically important arrhythmia mechanisms and some drugs do cause lethal arrhythmias through potassium channel blockade, the primary and most clinically relevant mechanism of TCA cardiac toxicity is sodium channel blockade causing QRS widening, not potassium channel blockade causing QT prolongation.
Option C: Option C is incorrect. Sodium-potassium ATPase inhibition is the mechanism of cardiac glycosides such as digoxin, not TCAs. TCA cardiotoxicity operates through a pharmacologically distinct mechanism — fast sodium channel blockade — that is not analogous to digitalis toxicity.
Option D: Option D is incorrect. TCAs do block alpha-1 adrenergic receptors, producing orthostatic hypotension as a clinical adverse effect, and this blockade does contribute to hypotension in overdose. However, the primary life-threatening cardiac mechanism is sodium channel blockade causing arrhythmias, not distributive shock from vasodilation alone.
Option E: Option E is incorrect. L-type calcium channel blockade is the mechanism of calcium channel blocker drugs (verapamil, diltiazem, dihydropyridines) and does produce negative inotropy and bradycardia in overdose. TCAs do not exert their primary cardiac toxicity through L-type calcium channel blockade; their critical arrhythmogenic mechanism is fast sodium channel blockade.
13. A patient currently taking phenelzine for atypical depression requires initiation of a new serotonergic antidepressant after an inadequate response. The prescribing psychiatrist explains that a prolonged washout period is necessary before any serotonergic agent can be started. What is the pharmacological basis for the extended duration of this washout requirement?
A) Phenelzine is extensively bound to plasma proteins with a very long half-life, and the washout period reflects the time needed to reduce plasma drug concentrations below the threshold at which drug-drug interactions can occur.
B) Phenelzine undergoes enterohepatic recirculation that maintains biologically active plasma concentrations for weeks after the last dose, and the washout period corresponds to the time required for complete elimination of the recirculating drug fraction.
C) Phenelzine is a reversible MAO inhibitor that requires sustained plasma concentrations to maintain enzyme inhibition; once phenelzine is eliminated after approximately two weeks, MAO activity returns to normal because the enzyme itself is structurally intact.
D) Phenelzine irreversibly inactivates MAO through covalent modification of the enzyme; normal MAO function is not restored until new enzyme is synthesized, a process requiring approximately two weeks, making the washout duration dependent on enzyme turnover rather than drug elimination.
E) Phenelzine inhibits CYP2C19, the enzyme responsible for metabolizing most serotonergic antidepressants; the two-week washout reflects the time needed for CYP2C19 activity to fully recover so that the subsequent antidepressant can be metabolized at a normal rate.
ANSWER: D
Rationale:
Option D is correct. Phenelzine and other irreversible MAOIs — including tranylcypromine and isocarboxazid — inactivate MAO through covalent modification of the enzyme's active site. Because the bond is irreversible, the drug's duration of pharmacological effect is not limited by its own plasma half-life but by the rate at which the body synthesizes new MAO enzyme to replace the inactivated enzyme. New MAO synthesis requires approximately two weeks, meaning that MAO inhibitory activity persists well beyond the time when phenelzine itself has been cleared from plasma. This is the mechanistic basis for the two-week washout requirement: the interaction risk — specifically serotonin syndrome from combined MAO inhibition and serotonergic drug activity — persists for as long as MAO remains inactivated, regardless of measurable phenelzine plasma levels.
Option A: Option A is incorrect. The extended washout for irreversible MAOIs is not based on plasma drug concentration or protein binding. The drug itself can be essentially cleared from plasma within days; the washout requirement persists because the enzyme it modified remains inactivated. Plasma concentration thresholds are irrelevant once the irreversible inhibition has occurred.
Option B: Option B is incorrect. Enterohepatic recirculation maintaining active plasma concentrations for weeks is not a property of phenelzine. This explanation is pharmacokinetically incorrect for the MAOI class; the extended washout is enzyme-turnover-based, not concentration-based.
Option C: Option C is incorrect. This option misdescribes phenelzine as a reversible MAO inhibitor. Phenelzine is irreversible. Reversible MAO inhibition is the property of moclobemide, a reversible inhibitor of MAO-A (RIMA) used clinically in some countries. Reversible inhibitors do have shorter washout requirements because enzyme activity recovers as the drug is eliminated, which is precisely the pharmacological distinction between reversible and irreversible MAO inhibitors.
Option E: Option E is incorrect. While MAOIs do have some CYP interactions, the primary and clinically authoritative reason for the two-week washout before initiating serotonergic drugs is irreversible MAO enzyme inactivation with a two-week recovery time — not CYP2C19 inhibition. The interaction risk is serotonin syndrome from combined MAO inhibition and serotonin reuptake inhibition, not a pharmacokinetic drug interaction at CYP2C19.
14. A resident asks why venlafaxine is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI) but a patient taking 37.5 mg daily appears to have a clinical response profile more similar to an SSRI, without the norepinephrine-mediated effects such as increased blood pressure and heart rate. Which pharmacodynamic property of venlafaxine explains this observation?
A) Venlafaxine exhibits competitive inhibition at both SERT and NET with equal affinity across all doses; the apparent dose-dependency of noradrenergic effects reflects downstream receptor adaptation rather than differential transporter occupancy.
B) At low doses, venlafaxine selectively binds NET over SERT because NET has a higher affinity for venlafaxine at low plasma concentrations; only at higher plasma concentrations does SERT inhibition become pharmacologically relevant.
C) Venlafaxine behaves primarily as a serotonin reuptake inhibitor at lower doses because its affinity for SERT is substantially greater than for NET; clinically meaningful NET inhibition requires higher doses that achieve plasma concentrations sufficient to occupy NET to a therapeutically significant degree.
D) The dose-dependent shift from serotonergic to noradrenergic activity in venlafaxine occurs because higher doses induce CYP2D6 upregulation, producing more of the desvenlafaxine metabolite, which has higher NET affinity than the parent compound.
E) Venlafaxine requires conversion to an active metabolite by CYP3A4 to achieve NET inhibition; at low doses, CYP3A4 is saturated and the active metabolite is not produced in sufficient quantities, so only SERT inhibition from the parent drug occurs.
ANSWER: C
Rationale:
Option C is correct. Venlafaxine has substantially greater affinity for SERT than for NET. At lower doses — generally below approximately 150 mg per day — plasma concentrations are sufficient to achieve meaningful SERT occupancy but are insufficient to produce clinically significant NET inhibition. The drug behaves predominantly as a serotonin reuptake inhibitor at these lower doses, producing a clinical profile resembling an SSRI. At higher doses, plasma concentrations increase to the point where NET occupancy becomes clinically significant, adding the noradrenergic component that characterizes the full SNRI effect. This dose-dependency distinguishes venlafaxine from duloxetine and levomilnacipran, which achieve meaningful NET inhibition across their therapeutic dose ranges.
Option A: Option A is incorrect. Venlafaxine does not have equal affinity for SERT and NET; its SERT affinity is substantially greater. The dose-dependency of noradrenergic effects reflects differential transporter affinity and concentration-dependent receptor occupancy — not downstream receptor adaptation.
Option B: Option B is incorrect. This option inverts the pharmacological reality. Venlafaxine has higher affinity for SERT than for NET, not the other way around. At low plasma concentrations, SERT occupancy is achieved first; NET inhibition requires higher concentrations because NET affinity is lower.
Option D: Option D is incorrect. The dose-dependent shift from serotonergic to noradrenergic activity is an intrinsic pharmacodynamic property of venlafaxine's differential affinity for its two target transporters, not a CYP2D6 induction effect. While venlafaxine is metabolized by CYP2D6 to desvenlafaxine (O-desmethylvenlafaxine), this is a normal metabolic conversion at all doses, not a dose-dependent induction phenomenon that generates a qualitatively different pharmacological profile.
Option E: Option E is incorrect. Net inhibition by venlafaxine is not dependent on CYP3A4-mediated metabolite production. Venlafaxine itself inhibits NET at sufficient plasma concentrations. CYP3A4 does play a role in venlafaxine metabolism, but the pharmacodynamic dose-dependency described in this question is explained by differential SERT versus NET affinity, not by metabolite-dependent activity.
15. Tryptophan depletion studies — in which dietary manipulation transiently reduces plasma tryptophan and limits serotonin synthesis — have been used to test the monoamine hypothesis of depression. Which of the following findings from these studies is most important for understanding the limitations of the monoamine hypothesis?
A) Tryptophan depletion studies confirm the monoamine hypothesis completely by demonstrating that any reduction in serotonin precursor availability reliably triggers a full depressive episode in all healthy adult volunteers, establishing serotonin deficiency as both necessary and sufficient to cause depression.
B) Tryptophan depletion studies show that serotonin depletion worsens depression exclusively in patients currently taking SSRIs, suggesting that these drugs paradoxically sensitize patients to fluctuations in serotonin availability rather than producing a durable neurobiological correction.
C) Tryptophan depletion studies demonstrate that serotonin availability has no role in mood regulation; subjects with and without a history of depression respond identically to tryptophan depletion, indicating that the monoamine hypothesis lacks empirical support from experimental serotonin manipulation.
D) Tryptophan depletion studies support the monoamine hypothesis by showing that reduced serotonin availability produces depression in patients with active major depressive disorder who are currently drug-free, confirming that serotonin deficiency is the proximate cause of active depressive episodes.
E) Tryptophan depletion transiently worsens mood in individuals who have had a prior depressive episode or who are in remission on a serotonergic antidepressant, but does not reliably produce depression in healthy volunteers without a personal or family history of mood disorder, suggesting that serotonin deficiency is a vulnerability factor rather than a sufficient cause.
ANSWER: E
Rationale:
Option E is correct. Tryptophan depletion studies have shown that transient reduction in serotonin availability worsens mood in individuals with a prior depressive episode and in remitted patients maintained on serotonergic antidepressants, but does not reliably produce depression in healthy volunteers without a personal or family history of mood disorder. This finding has an important implication for the monoamine hypothesis: serotonin deficiency is not, by itself, sufficient to cause depression. It may represent a biological vulnerability factor in predisposed individuals — one that becomes clinically relevant when combined with genetic, psychological, and environmental risk factors — but it cannot explain why depression does not develop in the vast majority of people who experience transient reductions in serotonin availability. This limits the monoamine hypothesis as a complete pathophysiological model while preserving its validity as a pharmacological target hypothesis.
Option A: Option A is incorrect. Tryptophan depletion does not reliably produce full depressive episodes in all healthy volunteers; this is precisely the key negative finding that limits the hypothesis. If serotonin deficiency were both necessary and sufficient to cause depression, depletion in healthy individuals should reliably produce clinical depression, which it does not.
Option B: Option B is incorrect. Tryptophan depletion does not exclusively worsen mood in SSRI-treated patients; it also worsens mood in individuals with prior depression who are not currently on antidepressants. The finding is not limited to SSRI users, and describing SSRIs as paradoxically sensitizing patients is not an accurate characterization of what the depletion studies show.
Option C: Option C is incorrect. Tryptophan depletion studies do not show that serotonin has no role in mood; they show that its role is modulatory and context-dependent rather than constitutively causal. The selective worsening of mood in predisposed individuals is positive evidence for serotonin's modulatory role, not evidence of no role.
Option D: Option D is incorrect. Drug-free patients with active major depressive disorder are not the key population in which tryptophan depletion has been studied as a test of the monoamine hypothesis, and this option misrepresents the significance of the depletion findings. The clinically critical observation is the negative finding in healthy volunteers — not a positive finding confirming deficiency as the proximate cause.
16. A 55-year-old woman with recurrent major depressive disorder with melancholic features undergoes evaluation. Laboratory testing reveals elevated morning cortisol and failure to suppress cortisol after administration of dexamethasone. A colleague asks what pathophysiological framework this finding reflects and why it matters for understanding antidepressant mechanisms. Which of the following best describes the HPA axis dysregulation model of depression?
A) Patients with major depressive disorder, particularly those with melancholic or psychotic features, frequently show hypercortisolemia and non-suppression on the dexamethasone suppression test; chronic cortisol excess is neurotoxic to hippocampal neurons through glucocorticoid receptor-mediated mechanisms and may contribute to the hippocampal volume loss observed in recurrent depression. Antidepressants normalize HPA axis activity over a similar weeks-long timeline as clinical improvement.
B) HPA axis dysregulation in depression is a consequence rather than a contributor to the illness; elevated cortisol levels reflect the psychological stress of being depressed and normalize spontaneously within days of initiating any effective antidepressant treatment, confirming that HPA changes are purely reactive.
C) The dexamethasone suppression test is diagnostic for major depressive disorder with specificity exceeding 95%; a positive test result — defined as failure to suppress cortisol — confirms the diagnosis and is used in clinical practice to differentiate MDD from adjustment disorder and dysthymia.
D) Hypercortisolemia in depression acts primarily through mineralocorticoid receptors in the amygdala, enhancing fear consolidation and threat vigilance, while hippocampal neurons are specifically protected from glucocorticoid toxicity by elevated BDNF expression during active depressive episodes.
E) Cortisol excess in depression upregulates glucocorticoid receptors in the prefrontal cortex, increasing cortisol sensitivity and creating a self-amplifying loop that progressively worsens HPA axis dysregulation; antidepressants work primarily by downregulating prefrontal glucocorticoid receptors to interrupt this cycle.
ANSWER: A
Rationale:
Option A is correct. The HPA axis dysregulation model of depression is well-supported by the consistent finding that a significant proportion of depressed patients — particularly those with melancholic or psychotic features — show hypercortisolemia, failure to suppress cortisol on the dexamethasone suppression test (DST), and blunted ACTH response to corticotropin-releasing hormone (CRH) stimulation. Chronic cortisol excess is neurotoxic to hippocampal neurons through glucocorticoid receptor-mediated mechanisms, and this toxicity is a proposed contributor to the hippocampal volume reduction reliably observed in patients with recurrent or chronic depression. Antidepressant treatment normalizes HPA axis activity, and this normalization follows the same weeks-long timeline as clinical improvement — supporting a mechanistic relationship rather than epiphenomenal correlation.
Option B: Option B is incorrect. HPA axis dysregulation in depression is not simply reactive stress; it persists in many patients even after partial symptomatic improvement and represents a biological abnormality linked to recurrence risk. Normalization does not occur within days of treatment initiation; it follows the same weeks-long timeline as other adaptive processes associated with antidepressant response.
Option C: Option C is incorrect. The DST is not a diagnostic test with high specificity for MDD. Its sensitivity for melancholic depression is reasonable but its specificity is limited — DST non-suppression can occur in other psychiatric and medical conditions including dementia, malnutrition, and systemic illness. It is a research and pathophysiological tool, not a clinical diagnostic test used to differentiate depression subtypes at the bedside.
Option D: Option D is incorrect. While mineralocorticoid receptors do play a role in glucocorticoid signaling, the established mechanism of cortisol neurotoxicity in depression involves glucocorticoid receptor-mediated effects on hippocampal neurons — not mineralocorticoid receptor effects in the amygdala. The claim that BDNF protects hippocampal neurons during active depressive episodes inverts the established biology; BDNF is reduced in active depression and its restoration is associated with recovery.
Option E: Option E is incorrect. The established direction of glucocorticoid receptor effects in depression involves impaired glucocorticoid receptor function in hippocampal and hypothalamic circuits — contributing to inadequate feedback inhibition of cortisol secretion — not upregulation in the prefrontal cortex. Antidepressants have been associated with upregulation of glucocorticoid receptor expression, which would improve feedback inhibition and reduce hypercortisolemia, not downregulation as stated in this option.
17. Researchers studying a subset of patients with treatment-resistant depression find elevated circulating levels of interleukin-6, TNF-alpha, and C-reactive protein. They propose a mechanism by which peripheral inflammation reduces central serotonergic tone without directly crossing the blood-brain barrier. Which of the following correctly describes this mechanistic link between inflammation and reduced serotonin availability?
A) Inflammatory cytokines directly inhibit tryptophan hydroxylase in serotonergic neurons of the dorsal raphe nucleus by crossing the blood-brain barrier at circumventricular organs, reducing the rate of serotonin synthesis from tryptophan.
B) Inflammatory cytokines upregulate the enzyme indoleamine 2,3-dioxygenase (IDO), which diverts tryptophan away from the serotonin synthesis pathway toward the kynurenine pathway, reducing the availability of tryptophan as a precursor for central serotonin production.
C) Elevated TNF-alpha and IL-6 directly inhibit SERT expression on serotonergic terminals, reducing transporter density and paradoxically increasing synaptic serotonin concentrations; the resulting receptor desensitization ultimately reduces serotonergic tone despite elevated synaptic 5-HT.
D) Peripheral inflammatory cytokines activate the hypothalamic-pituitary-adrenal axis, elevating cortisol, which then independently reduces serotonin synthesis; the neuroinflammatory and HPA dysregulation models are therefore two names for the same mechanistic pathway.
E) C-reactive protein directly binds and sequesters tryptophan in the bloodstream as an acute phase reactant, preventing its transport across the blood-brain barrier and thereby reducing central serotonin synthesis independently of any enzymatic pathway.
ANSWER: B
Rationale:
Option B is correct. Inflammatory cytokines, including IL-6, TNF-alpha, and interferon-gamma, upregulate indoleamine 2,3-dioxygenase (IDO), an enzyme that catalyzes the first step of tryptophan degradation along the kynurenine pathway. When IDO is upregulated by inflammatory signaling, a greater proportion of available tryptophan is diverted into kynurenine and its downstream metabolites rather than being used for serotonin synthesis via the 5-hydroxytryptophan (5-HTP) pathway. Because tryptophan is the obligate precursor for central serotonin synthesis and crosses the blood-brain barrier in competition with other large neutral amino acids, reduced tryptophan availability produces reduced serotonergic tone — providing a mechanistic bridge between peripheral inflammation and central monoamine deficiency without requiring cytokines themselves to cross the blood-brain barrier. Elevated baseline CRP has been associated with poorer response to SSRIs in clinical studies.
Option A: Option A is incorrect. Inflammatory cytokines do not directly inhibit tryptophan hydroxylase in dorsal raphe neurons by crossing the blood-brain barrier as their primary mechanism of action. The established mechanism is peripheral IDO upregulation reducing tryptophan availability, not direct enzymatic inhibition within the central nervous system.
Option C: Option C is incorrect. Inflammatory cytokines do not inhibit SERT expression as a primary mechanism, and the description of reduced SERT density paradoxically increasing synaptic serotonin with subsequent desensitization is pharmacologically convoluted and not an established pathway in the neuroinflammation-depression literature. The established direction of the inflammatory effect is reduced serotonin precursor availability, not elevated synaptic 5-HT.
Option D: Option D is incorrect. While inflammatory cytokines can activate the HPA axis, and HPA dysregulation and neuroinflammation are both relevant to depression pathophysiology, they represent distinct mechanistic pathways that can operate in parallel and are not two names for the same process. The IDO/kynurenine mechanism operates independently of cortisol elevation and provides a direct link between cytokine signaling and serotonin precursor availability.
Option E: Option E is incorrect. C-reactive protein is an acute phase reactant that binds to phosphocholine and other ligands in the context of inflammation, but it does not directly sequester tryptophan in the bloodstream as a pharmacologically relevant mechanism. The established mechanism linking CRP-associated inflammation to reduced serotonergic tone is IDO upregulation and tryptophan diversion, not direct CRP-tryptophan binding.
18. A patient who has been taking paroxetine 40 mg daily for eight months runs out of her prescription over a holiday weekend and misses three doses. She calls reporting dizziness, electric shock sensations through her head and extremities, nausea, and irritability. A colleague asks why paroxetine and venlafaxine immediate-release carry the highest risk of discontinuation syndrome among commonly prescribed antidepressants, while fluoxetine is rarely associated with this syndrome even when abruptly stopped. Which pharmacokinetic property explains this difference?
A) Paroxetine and venlafaxine immediate-release undergo extensive first-pass metabolism, meaning that small reductions in hepatic blood flow during dose omission produce disproportionately large drops in plasma drug concentrations, whereas fluoxetine bypasses hepatic first-pass through sublingual absorption.
B) Paroxetine and venlafaxine immediate-release are selective for 5-HT3 receptors, and abrupt removal of 5-HT3 blockade triggers gastrointestinal and vestibular hypersensitivity; fluoxetine lacks 5-HT3 activity and therefore does not produce these symptoms on discontinuation.
C) Paroxetine and venlafaxine immediate-release have high affinity for SERT at low plasma concentrations; as plasma levels fall after missed doses, even a small reduction in SERT occupancy produces disproportionate rebound symptoms compared to fluoxetine, which maintains SERT occupancy at lower concentrations.
D) Paroxetine and venlafaxine immediate-release have short elimination half-lives, causing plasma concentrations to fall rapidly after missed doses and producing abrupt reductions in serotonergic tone; fluoxetine's extended half-life — prolonged further by its active metabolite norfluoxetine — provides a degree of self-tapering that substantially reduces discontinuation syndrome risk.
E) Paroxetine and venlafaxine immediate-release are renally eliminated and accumulate to higher-than-expected plasma concentrations in patients with normal renal function; abrupt discontinuation produces rapid clearance of this accumulated drug burden, generating a withdrawal-like state that fluoxetine, being hepatically eliminated, does not produce.
ANSWER: D
Rationale:
Option D is correct. The primary pharmacokinetic determinant of discontinuation syndrome risk among antidepressants is elimination half-life. Paroxetine has a relatively short half-life of approximately 21 hours and, unlike most SSRIs, autoinhibits its own metabolism through CYP2D6 inhibition, meaning that plasma concentrations can drop more steeply than predicted after missed doses. Venlafaxine immediate-release has a half-life of approximately five hours, among the shortest of any antidepressant. When doses of these agents are missed, plasma concentrations fall rapidly, producing abrupt reductions in serotonergic (and for venlafaxine, noradrenergic) tone that manifest as the characteristic discontinuation syndrome — including the electric shock-like "brain zaps," dizziness, nausea, and irritability described in this patient. Fluoxetine's half-life of one to four days for the parent compound, extended to seven to fifteen days for its active metabolite norfluoxetine, provides built-in self-tapering: plasma concentrations fall slowly even after complete discontinuation, allowing gradual receptor readjustment without an abrupt serotonergic withdrawal.
Option A: Option A is incorrect. Both paroxetine and fluoxetine undergo significant first-pass hepatic metabolism; this is not the pharmacokinetic distinction that explains differential discontinuation syndrome risk. Fluoxetine does not bypass first-pass metabolism through sublingual absorption.
Option B: Option B is incorrect. Discontinuation syndrome from paroxetine and venlafaxine is not explained by 5-HT3 receptor blockade. Paroxetine does have mild 5-HT3 antagonism, but the mechanism of discontinuation syndrome is primarily central serotonergic rebound from abrupt reduction in SERT inhibition following plasma concentration decline — driven by half-life, not receptor subtype specificity.
Option C: Option C is incorrect. The explanation in this option conflates SERT binding affinity with pharmacokinetic half-life. The relevant variable for discontinuation syndrome risk is the rate at which plasma concentrations fall after missed doses — a pharmacokinetic property — not the concentration-dependence of SERT occupancy.
Option E: Option E is incorrect. Paroxetine and venlafaxine are not renally eliminated; they undergo extensive hepatic metabolism. Neither accumulates specifically because of renal handling. Fluoxetine is also hepatically metabolized. The explanation in this option is pharmacokinetically incorrect for both drugs.
19. A clinical researcher reviewing the methodology of antidepressant registration trials notes that the Hamilton Depression Rating Scale (HAM-D) in its 17-item version was the standard primary outcome measure for most trials conducted between the 1960s and 1990s. A newer investigator asks about the key features and limitations of the HAM-D17. Which of the following correctly characterizes the HAM-D17?
A) The HAM-D17 is a self-report instrument completed by the patient independently at each visit; its primary advantage over clinician-administered scales is elimination of inter-rater variability, and remission is conventionally defined as a total score of 7 or below.
B) The HAM-D17 is a clinician-administered scale with good sensitivity for the cognitive and anhedonic features of depression; its primary limitation is that it was developed for research use and has not been validated for clinical practice outside trial settings.
C) The HAM-D17 is a clinician-administered instrument that has been the standard outcome measure in antidepressant clinical trials since the 1960s; remission is conventionally defined as a score below 7, and a known limitation is that it is weighted toward somatic and anxiety symptoms, reducing its sensitivity for cognitive and anhedonic features of depression.
D) The HAM-D17 uses a ten-item structure focused on core psychological symptoms of depression including sadness, pessimism, and inability to feel; its remission threshold of 10 or below was established in the original validation studies and has remained the standard in clinical trials.
E) The HAM-D17 is a self-report scale with high sensitivity for detecting antidepressant-related change; it was specifically designed to overcome the somatic weighting limitation of earlier clinician-rated scales and uses a seven-item structure focused on psychological core features.
ANSWER: C
Rationale:
Option C is correct. The Hamilton Depression Rating Scale in its 17-item version (HAM-D17) has been the standard clinician-administered primary outcome measure in antidepressant registration trials since its introduction in the 1960s by Max Hamilton. It requires clinician administration and training, which introduces inter-rater variability and limits practical use outside research settings. Remission is conventionally defined as a score of 7 or below (below 7) in trial contexts, and a total score above 24 indicates severe depression. A recognized limitation of the HAM-D17 is that its item selection and weighting emphasize somatic symptoms — insomnia, appetite changes, psychomotor disturbance, somatic anxiety — over the cognitive and anhedonic features that are increasingly recognized as important treatment targets in depression and that may be particularly prominent in certain depressive subtypes.
Option A: Option A is incorrect. The HAM-D17 is clinician-administered, not self-report. Self-report depression scales include the PHQ-9 and the Beck Depression Inventory (BDI). The remission threshold below 7 stated in this option is correct, but the administration method is wrong.
Option B: Option B is incorrect. The HAM-D17's limitation is not insufficient sensitivity for cognitive features per se — it does assess concentration and work functioning — but rather that its item weighting overemphasizes somatic and anxiety symptoms relative to cognitive and anhedonic features. Additionally, it has been used extensively in clinical settings, not solely in research trials.
Option D: Option D is incorrect. The ten-item structure focused on core psychological symptoms describes the Montgomery-Asberg Depression Rating Scale (MADRS), not the HAM-D17. The MADRS remission threshold is 10 or below. The HAM-D17 has 17 items and a remission threshold below 7.
Option E: Option E is incorrect. The description of a self-report scale specifically designed to overcome HAM-D somatic weighting with a focus on psychological core features also describes the MADRS, not the HAM-D17. The MADRS is clinician-rated but was explicitly developed to be more sensitive to antidepressant-related psychological change than the HAM-D.
20. A clinical trialist argues that the Montgomery-Asberg Depression Rating Scale (MADRS) has largely replaced the HAM-D17 as the primary outcome measure in contemporary antidepressant registration trials. Which of the following correctly describes the MADRS and explains the rationale for preferring it in clinical trials of antidepressants?
A) The MADRS is a self-report instrument with 17 items that covers both psychological and somatic dimensions of depression with equal weighting; it was developed to complement the HAM-D17 for use in primary care settings where clinician administration is impractical.
B) The MADRS is a clinician-rated scale with 21 items that assesses a broad range of depressive features including psychomotor symptoms and vegetative signs; its advantage over the HAM-D17 is greater coverage of somatic features of depression that respond early to antidepressant treatment.
C) The MADRS is a patient-rated scale with 10 items that is completed using a smartphone application at daily intervals; its continuous monitoring capability makes it more sensitive to antidepressant response than any weekly clinician-rated instrument.
D) The MADRS is a 17-item clinician-administered scale developed specifically for treatment-resistant depression; it includes items measuring suicidality and psychotic features that are absent from the HAM-D17, making it the preferred instrument when severity is extreme.
E) The MADRS is a ten-item clinician-rated scale developed specifically to be sensitive to antidepressant-related change; its items focus on core psychological symptoms of depression with relatively less emphasis on somatic symptoms than the HAM-D17, remission is conventionally defined as a score of 10 or below, and it has become the preferred primary outcome measure in many antidepressant registration trials.
ANSWER: E
Rationale:
Option E is correct. The Montgomery-Asberg Depression Rating Scale (MADRS) is a ten-item clinician-rated instrument developed by Stuart Montgomery and Marie Asberg and published in 1979, specifically designed to be sensitive to antidepressant-related change in clinical trials. Its ten items assess core psychological symptoms — apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts — with relatively less emphasis on somatic and anxiety-related symptoms compared to the HAM-D17. This focus makes the MADRS better suited to detecting psychological recovery from depression as it unfolds with antidepressant treatment, which is why it has become the preferred primary outcome measure in many contemporary registration trials. Remission is conventionally defined as a score of 10 or below.
Option A: Option A is incorrect. The MADRS is clinician-rated, not self-report, and has 10 items rather than 17. Self-report scales include the PHQ-9 and the Patient Health Questionnaire. The MADRS was developed for research trial settings rather than primary care convenience.
Option B: Option B is incorrect. The MADRS has 10 items, not 21. Its advantage over the HAM-D17 is not greater somatic coverage but rather greater focus on psychological features and stronger sensitivity to antidepressant-related change. Greater somatic weighting is a characteristic limitation of the HAM-D17, not the advantage of the MADRS.
Option C: Option C is incorrect. The MADRS is a clinician-rated scale, not a patient self-report scale completed via smartphone application. Daily digital monitoring of mood is a feature of ecological momentary assessment research tools and does not describe the MADRS.
Option D: Option D is incorrect. The MADRS has 10 items, not 17. It was not developed specifically for treatment-resistant depression; it was developed as a general antidepressant trial outcome measure sensitive to change. The HAM-D17 does include items on somatic and anxiety features that the MADRS de-emphasizes; describing the MADRS as having superior coverage of severity extremes is not the basis for its preference in trials.
21. A family medicine resident asks what the best available evidence says about the likelihood that a patient with major depressive disorder will achieve remission on the first antidepressant prescribed. She has read that most patients respond to the first agent tried and wants to set realistic expectations before counseling a new patient. Which of the following best characterizes what the STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression) demonstrated about first-step antidepressant outcomes?
A) The STAR*D trial demonstrated that only approximately one-third of patients with major depressive disorder achieved remission on the first antidepressant tried, reinforcing the clinical importance of systematic response monitoring and a structured approach to next-step decisions when the initial agent fails.
B) The STAR*D trial demonstrated that approximately two-thirds of patients with major depressive disorder achieved full remission on the first antidepressant prescribed, confirming that most patients can expect symptom-free recovery with first-line pharmacotherapy.
C) The STAR*D trial demonstrated that antidepressant response rates are equivalent across all drug classes and doses, and that the choice of first-line agent has no meaningful impact on the likelihood of remission at four to six weeks.
D) The STAR*D trial demonstrated that remission rates on the first antidepressant correlate directly with baseline PHQ-9 score, with patients scoring below 15 achieving remission in over 80% of cases while those scoring above 20 rarely remit on any pharmacological agent.
E) The STAR*D trial demonstrated that switching antidepressant classes after the first agent fails produces significantly higher remission rates than augmenting the initial agent, establishing class-switching as the evidence-based standard for second-step treatment.
ANSWER: A
Rationale:
Option A is correct. The STAR*D trial — Sequenced Treatment Alternatives to Relieve Depression — was a large, multisite, prospective study funded by the National Institute of Mental Health that examined real-world antidepressant outcomes across sequential treatment steps. At the first treatment step, using citalopram as the initial agent, only approximately one-third of participants achieved remission, defined by a QIDS-SR score of 5 or below. This finding was influential in establishing that the majority of patients with MDD do not achieve remission on the first antidepressant tried and require systematic reassessment, dose adjustment, augmentation, or switching to achieve the treatment goal of remission. This evidence base reinforces the importance of measurement-based care and structured next-step decision frameworks rather than passive continuation of an inadequate initial regimen.
Option B: Option B is incorrect. Approximately two-thirds achieving remission on the first antidepressant inverts the STAR*D finding. Roughly one-third remitted on the first step; approximately two-thirds required additional treatment steps or did not achieve remission despite multiple steps.
Option C: Option C is incorrect. STAR*D did not demonstrate that remission rates are equivalent across all drug classes and doses, nor was it designed to compare drug classes against each other — all participants in step 1 received citalopram. The absence of between-class comparison at step 1 is a methodological feature of the trial design, not a finding that class equivalence was demonstrated.
Option D: Option D is incorrect. STAR*D did not demonstrate a threshold-based remission rate correlated directly with baseline PHQ-9 score in the manner described. Baseline severity did influence outcomes, but the claim of specific remission percentages at specific PHQ-9 thresholds in this option is not an established STAR*D finding.
Option E: Option E is incorrect. STAR*D was not designed as a head-to-head comparison of switching versus augmentation strategies in a single trial arm; subsequent steps in STAR*D compared several options including switching and augmentation, but the trial's findings do not establish a universal superiority of class-switching over augmentation as the standard second-step approach.
22. A 68-year-old woman with advanced liver cirrhosis and a serum albumin of 1.8 g/dL is started on sertraline at a standard dose of 50 mg daily for major depressive disorder. Three weeks later she is experiencing symptoms consistent with sertraline toxicity despite a measured plasma drug concentration within the reported therapeutic range. Which pharmacokinetic principle best explains how toxicity can occur at a seemingly therapeutic total plasma concentration?
A) Hepatic cirrhosis reduces CYP2D6 activity specifically, impairing sertraline's conversion to its active metabolite; the elevated parent-drug level detected in the therapeutic range actually represents an inactive form, and a separate unmeasured active fraction accumulates to toxic levels.
B) Advanced liver disease reduces gastric acid secretion, increasing the oral bioavailability of sertraline beyond its normal range and producing higher post-absorption plasma concentrations than the dose was expected to generate.
C) Most antidepressants are highly protein-bound, predominantly to albumin; in hypoalbuminemia from hepatic cirrhosis, the free (unbound) drug fraction increases substantially even when total plasma drug concentration appears normal, and it is the free fraction that crosses the blood-brain barrier, distributes into tissues, and exerts pharmacological effects.
D) Cirrhosis produces portal hypertension that accelerates hepatic arterial blood flow through the liver, paradoxically increasing first-pass metabolism of sertraline and producing a toxic breakdown product that accumulates in proportion to portal pressure.
E) Sertraline binds irreversibly to albumin in healthy patients; when albumin is reduced in cirrhosis, a larger proportion of the dose remains unbound to albumin and is instead bound to alpha-1-acid glycoprotein at a site with five-fold higher pharmacological potency, explaining the toxic effect at normal total concentrations.
ANSWER: C
Rationale:
Option C is correct. Antidepressants as a class are highly protein-bound, predominantly to albumin and alpha-1-acid glycoprotein (AAG), with free fractions typically between 1% and 10% under normal circumstances. It is the free (unbound) drug fraction, not the total plasma concentration, that is pharmacologically active — only free drug crosses the blood-brain barrier, distributes into tissues, and interacts with target receptors. In states of reduced protein binding such as hypoalbuminemia from malnutrition, advanced hepatic disease, or nephrotic syndrome, the free drug fraction increases substantially. Standard plasma drug concentration measurements report total drug — bound plus free — and in a hypoalbuminemic patient, the same total concentration contains a much larger free fraction than it would in a patient with normal albumin. This patient is therefore experiencing a significantly higher effective drug exposure than the total plasma concentration suggests, explaining toxicity within the apparent therapeutic range.
Option A: Option A is incorrect. Sertraline is not a prodrug that requires CYP2D6 activation; it is active as the parent compound. CYP2D6 does contribute to sertraline metabolism, but impaired CYP2D6 activity in cirrhosis would reduce sertraline clearance and raise total plasma concentrations rather than producing a separate unmeasured toxic form.
Option B: Option B is incorrect. Gastric acid secretion and oral bioavailability are not the primary pharmacokinetic concerns with sertraline in advanced cirrhosis. While hepatic first-pass metabolism may be impaired in cirrhosis, raising bioavailability, the scenario specifies that plasma concentrations are within the therapeutic range — suggesting that total drug accumulation from impaired first-pass is not the proximate explanation. The free fraction elevation from hypoalbuminemia is the more direct and pharmacologically precise explanation.
Option D: Option D is incorrect. Portal hypertension in cirrhosis does not accelerate hepatic arterial flow in a manner that increases first-pass metabolism; rather, portosystemic shunting in cirrhosis typically bypasses hepatic metabolism and reduces first-pass extraction, increasing bioavailability. The mechanism described is pharmacokinetically inverted.
Option E: Option E is incorrect. Drug binding to albumin is reversible, not irreversible — reversible binding is fundamental to how protein-bound drugs release free drug for distribution and activity. Sertraline does not bind irreversibly to albumin, and there is no established high-potency binding site on alpha-1-acid glycoprotein that accounts for toxicity in this context.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.